G20 Health & Development Partnership
The G20 Health & Development Partnership emerged over several months of consultation and policy dialogue that included a lynchpin “G20 Global Health Innovation” roundtable in Berlin on April 28th, 2017. The Partnership Initially functioned as an informal coalition of like-minded organisations – the Global Alliance for TB Drug Development (TB Alliance), Medicines for Malaria Venture (MMV), the Sabin Vaccine Institute, the Coalition for Epidemic Preparedness Innovations (CEPI), PATH, Sovereign Strategy, the Global Health Technologies Coalition (GHTC), the Global Health Innovative Technology (GHIT) Fund, Unitaid and the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). The event brought together a wider eclectic group of experts representing a broad set of international partnerships, with discussions culminating in a Rapporteur’s Report as well as a Call to Action signed by over a hundred individuals and organizations.
Following broad interest to build on the initiative, Sovereign Sustainability and Development (SSD) was created in late 2017 to act as the convener and secretariat of the Partnership. Following consultation with a number of key stakeholders and confirmation from the Government of Argentina that health would remain a focus of the G20 under its Presidency, a Working Session was scheduled in the UK Houses of Parliament in December 2017 in order to collectively plot a course for the Partnership.
Those present acknowledged and welcomed the continued inclusion of global health on the G20 agenda and emphasized that, as the SDGs guide much of the work of the G20 across all thematic areas, it is important to remain inclusive to a wider constituency. Just as the objective in 2017 was to support the German Presidency, the objective in 2018 is to support the Argentinian Presidency. Involvement in the Working Session by several G20 member governments including the London Embassies of Germany and Argentina in addition to an esteemed group of cross-party members of both houses of the UK Parliament ensured a rich and rewarding exchange.
As the G20 will continue its focus on areas such as health emergencies, UHC and antimicrobial resistance (AMR), from the German Presidency through the Argentinian Presidency and into the Japanese Presidency (the three representing the current Troika of the G20) the Partnership will seek to add value and support these areas of prioritization and drive political support to deliver on the Declarations related to them. The Partnership will maintain a focus on the broader innovation ecosystem – R&D for new tools, new ways of delivering treatment and changing behaviour, improving health systems, new ways of working to connect various global health stakeholders and models of finance to fund global health in order to meet the SDGs. The Partnership aims to align with and support the relevant aspects of the WHO’s thirteenth general programme of work (GPW).
FAQs
What is the G20 Health and Development Partnership?
The G20 Health and Development Partnership is a group of organizations with common interests and objectives. The Partnership emerged on an informal basis initially functioning as a coalition of like-minded organisations - the Global Alliance for TB Drug Development (TB Alliance), Medicines for Malaria Venture (MMV), the Sabin Vaccine Institute, the Coalition for Epidemic Preparedness Innovations (CEPI), PATH, Sovereign Strategy, the Global Health Technologies Coalition (GHTC), the Global Health Innovative Technology (GHIT) Fund, Unitaid and the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) - that sponsored a “G20 Global Health Innovation” roundtable in Berlin on April 28th, 2017. This roundtable brought together the sponsors and a wider group of experts representing a broad set of international partnerships, with discussions culminating in a Rapporteur's Report as well as a Call to Action signed by over a hundred individuals and organizations.
What is Sovereign Sustainability and Development?
Sovereign Sustainability and Development (SSD) is a UK private limited company that was created in late 2017 to act as the convener and secretariat of the G20 Health and Development Partnership. Following consultation with a number of key stakeholders and confirmation from the Government of Argentina that health would remain a focus of the G20 under its Presidency in 2018, Sovereign Strategy - the organization that had provided secretarial pro-bono support to the Partnership in 2017 - created a related entity to provide comprehensive management of the Partnership during its consequential phase and to reflect the increasing focus of its mandate and expertise in the sustainable development field.
What are the benefits of joining the Partnership?
Partnership members benefit from being integrated into the mission, vision and strategic objectives as outlined in the Strategic Objectives of the Partnership as outlined under section “G20 Health and Development Partnership”. Partners will have the unique opportunity to raise their excellent work and issues in the collaborative platform that SSD is creating to enable a first-class cross- sectorial dialogue among partners. With the organisation of high-level events throughout its strategic year, SSD will bring partners together with high-level policymakers, beyond the G20. Partners will have the opportunity to continuously contribute to the strategic direction of the Partnership and benefit from the Partnership as a platform which facilitates the pursuit of individual as well as collective objectives.
How can your organization join the G20 Health and Development Partnership?
We welcome the engagement of public, private, not-for-profit and academic organisations from all countries. After submitting a formal request on our SSD website, under the section “Join Us” our team will contact you shortly.
How long does membership last?
Membership fees are based on an annual (12 month) calendar year basis upon being an official member. Different rates apply for the private, public and not-for-profit sectors in high-, middle- and low-income countries. Our rates follow the official work bank classifications.
How are fees used for the G20 Global Health and Development Partnership?
Membership fees are solely used to ensure that the Partnership is able to pursue its strategic objectives. All funds are invested directly into the management of the Partnership with any deficit covered by the secretariat and any surplus reinvested into the Partnership. No fees are used for direct lobbying purposes.
Are travel expenses to related events covered by fees?
Travel and related expenses are not covered by membership fees for members.